8 completed, 5 active not recruiting, 5 recruiting, 3 terminated. 9 Not applicable, 4 Phase 2, 4 Phase 4, 3 Phase 3, 1 Early Phase 1.
Follow Autosomal Dominant Polycystic Kidney: new trials by email Literature Review of Autosomal Dominant Polycystic Kidney trials Research Report on Autosomal Dominant Polycystic Kidney
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease GBP-213 - Autosomal Dominant Polycystic Kidney | Early Phase 1 | Not yet recruiting | RenJi Hospital | 24 | 2026-11-01 | 2026-10-23 |
| Glucagon-Like Peptide-1 Receptor Agonist in ADPKD Tirzepatide, Placebo - Autosomal Dominant Polycystic Kidney, Obesity | Phase 2 | Recruiting | University of Colorado, Denver | 126 | 2025-03-06 | 2025-05-06 |
| Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD) Empagliflozin 10 MG, Placebo - Autosomal Dominant Polycystic Kidney | Phase 4 | Active not recruiting | Hannover Medical School | 44 | 2024-06-14 | 2025-11-24 |
| Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases Skin biopsy - Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis | Not applicable | Recruiting | Mario Negri Institute for Pharmacological Research | 105 | 2024-02-21 | 2026-03-23 |
| Outcome of ADPKD With Octreotide LAR Octreotide - Autosomal Dominant Polycystic Kidney | Active not recruiting | Mario Negri Institute for Pharmacological Research | 70 | 2024-02-12 | 2025-09-05 | |
| Thyroid Hormones in ADPKD Blood sampling - Autosomal Dominant Polycystic Kidney | Not applicable | Completed | Mario Negri Institute for Pharmacological Research | 91 | 2023-02-01 | 2024-03-28 |
| Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD Daily caloric restriction, Standard advice control - Autosomal Dominant Polycystic Kidney | Not applicable | Active not recruiting | University of Colorado, Denver | 14 | 2023-01-13 | 2026-05-01 |
| Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts aspiration sclerotherapy versus laparoscopic fenestration - Liver Cyst, Polycystic Liver Disease | Not applicable | Unknown | Radboud University Medical Center | 70 | 2022-10-01 | 2023-04-05 |
| A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease Leuprorelin - Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney | Phase 2 | Recruiting | University Medical Center Groningen | 36 | 2022-06-01 | 2022-11-04 |
| Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease Beetroot juice, Nitrate-depleted beetroot juice - Autosomal Dominant Polycystic Kidney, Hypertension | Not applicable | Completed | Western Sydney Local Health District | 60 | 2022-05-05 | 2025-06-08 |
| Treatment of Vascular Stiffness in ADPKD Sodium chloride (NaCl), Placebo, Amiloride Hcl 5mg Tab - Autosomal Dominant Polycystic Kidney | Phase 4 | Completed | Erasmus Medical Center | 46 | 2022-03-11 | 2025-08-17 |
| Daily Caloric Restriction in ADPKD Daily caloric restriction, Standard advice control - Autosomal Dominant Polycystic Kidney, Overweight and Obesity | Not applicable | Active not recruiting | University of Colorado, Denver | 125 | 2021-11-03 | 2025-08-12 |
| Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease Lixivaptan, Placebo - Autosomal Dominant Polycystic Kidney, ADPKD | Phase 3 | Terminated | Palladio Biosciences | 12 | 2021-10-28 | 2023-02-06 |
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers AL01211 or Placebo (Part A), AL01211 or Placebo (Part B) - Autosomal Dominant Polycystic Kidney | Phase 1 | Completed | AceLink Therapeutics, Inc. | 69 | 2021-06-08 | 2022-10-14 |
| Analysis of Patients With Autosomal Dominant Polycystic Kidney Autosomal Dominant Polycystic Kidney, ADPKD | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 180 | 2021-02-20 | 2025-01-06 | |
| Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt Sodiumchloride, Protein, Placebo comparator (salt) - Polycystic Kidney, Autosomal Dominant, ADPKD | Not applicable | Unknown | Esther Meijer | 12 | 2020-09-07 | 2020-11-05 |
| Dietary Intervention in ADPKD on Tolvaptan Dietary - Polyuria, Autosomal Dominant Polycystic Kidney | Not applicable | Completed | McMaster University | 8 | 2019-06-06 | 2024-03-15 |
| A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON Bardoxolone methyl oral capsule, Placebo oral capsule - Autosomal Dominant Polycystic Kidney, ADPKD | Phase 3 | Terminated | Biogen | 667 | 2019-05-29 | 2025-06-03 |
| An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) Bardoxolone methyl - Chronic Kidney Diseases, Alport Syndrome | Phase 3 | Terminated | Biogen | 270 | 2019-03-08 | 2025-06-03 |
| Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease Tolvaptan - Autosomal Dominant Polycystic Kidney | Phase 4 | Unknown | Lisbet Brandi | 90 | 2018-09-12 | 2018-11-26 |
Showing 20 of 25. Sign in to see all of them.
Polycystic Kidney, Autosomal Dominant (25) · Hypertension (2) · Obesity (2) · Polycystic Kidney Diseases (2) · Polycystic liver disease (2) · Atypical Hemolytic Uremic Syndrome (1) · Glomerulonephritis, IGA (1) · Glomerulonephritis, Membranoproliferative (1) · Glomerulosclerosis, Focal Segmental (1) · Kidney Diseases (1) · Nephritis, Hereditary (1) · Overweight (1) · Polyuria (1) · Renal Insufficiency, Chronic (1)
Abnormalities, Multiple (25) · Ciliopathies (25) · Congenital Abnormalities (25) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (25) · Female Urogenital Diseases (25) · Female Urogenital Diseases and Pregnancy Complications (25) · Genetic Diseases, Inborn (25) · Kidney Diseases, Cystic (25) · Male Urogenital Diseases (25) · Urogenital Diseases (25) · Urologic Diseases (25) · Kidney Diseases (24) · Polycystic Kidney Diseases (23) · Pathological Conditions, Signs and Symptoms (4) · Nephritis (3)
bardoxolone methyl (3) · Amiloride (1) · Blood Specimen Collection (1) · Diet (1) · Leuprolide (1) · Octreotide (1) · Pravastatin (1) · Proteins (1) · Salts (1) · Sodium Chloride (1) · Sodium Chloride, Dietary (1) · Tirzepatide (1) · Tolvaptan (1) · XL647 (1) · empagliflozin (1)
University of Colorado, Denver (4) · Biogen (3) · Mario Negri Institute for Pharmacological Research (3) · AceLink Therapeutics, Inc. (1) · Erasmus Medical Center (1) · Esther Meijer (1) · Hannover Medical School (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Kadmon, a Sanofi Company (1) · Lisbet Brandi (1) · Mayo Clinic (1) · McMaster University (1) · Palladio Biosciences (1) · Radboud University Medical Center (1) · RenJi Hospital (1)
United States (11) · Australia (5) · Italy (5) · Netherlands (4) · Spain (3) · France (2) · Germany (2) · Japan (2) · United Kingdom (2) · Belgium (1) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1)
Esther Meijer, Dr. (1) · G K Rangan (1) · Gaetano La Manna, MD (1) · Giuseppe Remuzzi, MD (1) · Joost P.H. Drenth (1) · Kristen Nowak, PhD, MPH (1) · Leyi Gu (1) · Lisbet Brandi, MD DMSc MHM (1) · M. Salih, MD, PhD (1) · Marie Hogan, MD, PhD (1) · Marina Noris, PhD (1) · Martin Prince, MD (1) · Michel Chonchol, MD (1) · Philip Ryan, MBBS, FRACP (1)
PMID 39356039, PMID 41385299, PMID 41348481, PMID 37507763, PMID 37729939, PMID 38151173, PMID 38556640, PMID 39675824, PMID 39970002, PMID 40377984, PMID 41077128, PMID 42296046
2018 (1), 2023 (1), P30DK048520 (1), R01DK129259 (1), R01DK138915 (1)